drugset
drugset / Trial / NCT03948568

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

NCT03948568 ↗

Phase 4 Completed 262 enrolled Ottawa Hospital Research Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

REaCT-RETT will demonstrate the non-inferiority of concurrent compared to sequential endocrine therapy in patients receiving post-operative radiotherapy for early stage breast cancer.

Timeline

Start
2019-09-17
Primary completion
2021-06-09
Completion
2022-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified — —
Subject Exemestane Small molecule — —
Subject Letrozole Other / unclassified — —
Subject Tamoxifen Small molecule — —

Indications

female breast carcinoma